An interventional study of Base intervention and Augmented Intervention in CARDIOMETABOLIC CONDITIONS, Obesity and Pre-diabetes, sponsored by University of Illinois at Chicago. Active, not recruiting at 3 sites in United States. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Obesity by University of Illinois at Chicago — 6 open to participants now, 8 under way, none of them phase 3. Obesity · University of Illinois at Chicago.
Among the 35 studies in Obesity by University of Illinois at Chicago, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2023, is one of 29 with no phase, and was the 29th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →6 of the 35 studies in Obesity by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:
University of Illinois at Chicago · Sites in United States
University of Illinois at Chicago · Sites in United States
Ages 50–79 · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 50–74
University of Illinois at Chicago · Sites in United States
Ages 18–40 · Women only
University of Illinois at Chicago · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 50 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,029 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 90 across the 33 interventional studies, 38 across the 2 observational. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
4 of the studies in Obesity by University of Illinois at Chicago that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654142University of Illinois at ChicagoThe PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older | 2026-12-31 |
| NCT05199454University of Illinois at ChicagoRole of Adiposomes in Endothelial Dysfunction | 2026-12-31 |
| NCT05114798University of Illinois at ChicagoTime-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers | 2027-03-31 |
| NCT05234125University of Illinois at ChicagoBetter Lifestyle Counseling for African American Women During Pregnancy | 2027-09-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Obesity by University of Illinois at Chicago, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.
Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.
This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.
English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with \<3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).
The investigators hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed (BMI) ≥27.0 based on:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.
Behavioral: Base intervention
Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.
Behavioral: Augmented Intervention
Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
Behavioral: Base intervention
Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
Behavioral: Base intervention
Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.
Behavioral: Augmented Intervention
12 Group Lifestyle Balance videos and digital motivational messages
12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
Assess change in weight from baseline to 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Baseline, 52 weeks
Assess change in weight from baseline to 12 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 12 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Baseline, 12 weeks,
Assess trajectories of weight change from baseline to 6, 12, 24, and 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0), 6, 12, 24, and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks
Assess changes in number of steps using Fitbit activity tracker at 6, 12, 24 and 52 weeks
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored number of steps using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep metrics using Fitbit activity tracker at 6, 12, 24 and 52 weeks
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in physical activity using the International Physical Activity Questionnaire at 6, 12, 24 and 52 weeks
All participants will self-administer the International Physical Activity Questionnaire (IPAQ), a 7-item questionnaire that captures a participant's physical activity over the last 7 days.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in fruit/veggie/fat/fiber intake at 6, 12, 24 and 52 weeks
Dietary intake will be measured using 17-item fruit, vegetable, fat, and fiber screener by self-report. Correlations between screener estimates and estimated true intake were 0.5-0.8.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in weight control at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for weight control using the Weight Efficacy Lifestyle Questionnaire. Sum of scores of 8 items, with a range between 0 and 80. Higher scores indicate higher self-efficacy to control eating behaviors.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for dietary change using the Eating Habits Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher diet self-efficacy (i.e., higher ability to avoid eating certain unhealthy foods).
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in physical activity at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for physical activity using the Exercise Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher exercise self-efficacy (i.e., greater confidence in performing certain behaviors consistently for at least 6 months).
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in social support/autonomous support per Health Care Climate Questionnaire at 6, 12, 24 and 52 weeks
Participants will complete the Health Care Climate Questionnaire (HCCQ), which assessed their perceptions of the autonomy supportiveness of their care team. HCCQ contains 15 items, rated on a 5-point scale ranging from "not true at all" to "very true." After reversing the score of a negative item, an average score is calculated with higher score indicating a higher level of perceived autonomy support.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in problem solving ability at 6, 12, 24 and 52 weeks
Participants' problem solving abilities will be assessed using the reliable and valid SPSI-R:S that contains 25 items in the following 5 subscales: positive problem orientation (PPO), negative problem orientation (NPO), rational problem solving (RPS), impulsive/careless style (ICS), and avoidance style (AS). Each item is rated on a 5-point scale ranging from "not at all true of me" (0) to "extremely true of me" (4). SPSI-R:S is a short version of the long SPSI-R:L form which has Cronbach's alpha coefficient of 0.95 for the total score and of 0.67-0.92 for subscales.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in patient activation at 6, 12, 24 and 52 weeks
The 13-item PAM measures patient's self-reported knowledge, skill, and confidence for self-managing his or her health condition. It demonstrated acceptable internal consistency (Conbrach's alpha = 0.81). The 13-item PAM score accounts for 92% of the variation in the activity measured by the original 22-item PAM. The score is also significantly correlated with general preventive behaviors and disease-specific self-management behaviors.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in perceived stress at 6, 12, 24 and 52 weeks
Perceived Stress Scale (PSS) measures the perception of stress (i.e., the degree to which situations in one's life are appraised as stressful). PSS contains 14 items, rated on a 5-point scale ranging from "never" to "very often." After reversing the scores on 7 positive items, a sum of score is calculated with higher score indicating higher perceived stress. Cronbach's alpha ranged from 0.84 to 0.86.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep disturbance score at 6, 12, 24 and 52 weeks
Sleep disturbance is assessed on the 8-item PROMIS sleep disturbance scale short form which measures symptoms of insomnia. Each item is scaled from 1 (not at all) to 5 (very much). Sleep disturbance score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep disturbance.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep impairment score at 6, 12, 24 and 52 weeks
Sleep impairment is assessed on the 8-item PROMIS sleep-related impairment scale short form which measures symptoms of daytime sleepiness. Each item is scaled from 1 (not at all) to 5 (very much). Sleep impairment score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep impairment.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks
Cognitive functioning will be assessed on the PROMIS version 1.0 short-form subscales of Cognitive Abilities and Cognitive Concerns. Each subscale contains 8 items. The Cognitive Abilities items target positive self-assessments of cognitive functioning such as "My memory has been as good as usual" and "I have been able to concentrate." The Cognitive Concerns items are worded negatively and express concerns in the same areas, for examples, "My thinking has been slow" and "I have had trouble shifting back and forth between different activities that require thinking." Items on both subscales use a 5-point rating from "not at all" to "very much." Items are summed to create a total score for each subscale.
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cardiovascular risk at 52 weeks
The non-laboratory Framingham risk prediction model estimates individuals' 10-year risk of developing any major atherosclerotic cardiovascular disease (CVD) event. The component risk factors are age, BMI, systolic blood pressure, smoking status, presence of diabetes, and medication for high blood pressure. Participants will be asked to confirm their age and report their smoking history at baseline and current smoking status at baseline and 52 weeks. The BMI will be calculated based on participants' self-measured weight data as described above and height measurements abstracted from their EHR. Blood pressure, diagnosis of diabetes, and prescriptions for high blood pressures will also be abstracted from the EHR.
Time frame: Baseline, 52 weeks
Assess changes in number/severity of comorbidity at 52 weeks
The Cumulative Illness Rating Scale (CIRS) is a composite index of the number and severity of medical problems by organ system. It has been validated in diverse populations and settings, including primary care patients, with published guidelines and electronic tools for application and scoring using electronic health record (EHR) data.
Time frame: Baseline, 52 weeks
GLB videos viewed
GLB videos viewed will be automatically tracked.
Time frame: Throughout the intervention, up to 1 year
PST coaching sessions completed
PST coaching sessions completed will be recorded by coach in REDCap.
Time frame: Throughout the intervention, up to 1 year
Self-monitoring of weight
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). Participants will be encouraged to weigh themselves at least 3 days a week throughout the study. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible) at consistent time. They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Through study completion, an average of 1 year
Self-monitoring of activity & sleep
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. Participants will be encouraged to wear their activity tracker for at least 10 hours on 3 or more days a week throughout the study. The investigators will obtain participants' self-monitored number of steps and sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.
Time frame: Through study completion, an average of 1 year
Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →